Scan: Will Trump make IVF free? — Before 2029

date	predicted	market price	confidence
2026-08-29	12%	13%	69%
2026-08-22	13%	15%	65%
2026-08-15	10%	13%	70%

1. Planner Fable 5.1 · Fermi decomposition + tool plan

Tools chosen: kalshi_direct claude_news kalshi_related polymarket_related congress_bills gdelt_news wikipedia

Sub-questions (Fermi decomposition)

What is the current Kalshi price for KXFREEIVF-29 and how has it trended since Trump's Feb 2025 and Oct 2025 IVF announcements?
What concrete actions has the Trump administration taken on IVF so far (Feb 2025 executive order, Oct 2025 TrumpRx drug-discount deal, TRICARE/federal employee coverage changes), and do any of them fully eliminate out-of-pocket cost for a cycle?
Is there pending federal legislation (e.g., IVF mandate or federal subsidy bills in the 119th Congress) that could pass and be signed before 2029, and what is its status?
Has the White House or HHS signaled a further rule, mandate (e.g., employer coverage mandate via ACA essential health benefits), or direct-payment program with a timeline before 2029?
How does Kalshi's resolution language treat partial measures (drug discounts, insurance mandates with copays, coverage only for specific populations like military/federal employees) versus a truly 'free' cycle?
Does Polymarket or other Kalshi markets price the same or related IVF questions, and do they agree with the Kalshi price?
What is the base rate of presidents delivering on high-profile healthcare cost-elimination campaign promises within a single term?

Planner reasoning

This is a long-horizon Kalshi policy question about whether Trump takes an action eliminating the cost of at least one IVF cycle before Jan 20, 2029. Key drivers are the current status of Trump's IVF executive orders (Feb 2025 EO, Oct 2025 TrumpRx/EMD Serono announcement), whether any federal mandate or subsidy program actually reaches zero out-of-pocket cost, and how Kalshi's resolution criteria interpret 'eliminates the cost.' I anchor on the Kalshi price, triangulate with Polymarket, and use news and legislation searches to gauge the policy pipeline.

2. Research Parallel tool calls

tool	status	time	items	summary
kalshi_direct	OK	0.3s	1	## This Market's Kalshi Data Before 2029 (KXFREEIVF-29) - Current price (probability): 13.00% - 7-day price change: +0.00% - 30-day price change: -3.00% - Average daily volume: 120 contracts - Price range: 9.00% - 39.00% - Data points: 277 days
claude_news	OK	21.6s	15	## Findings on Trump's IVF affordability promise (as of mid-2026) - Feb 2025 executive order (EO 14216) simply asked the Deputy Domestic Policy Advisor to make policy recommendations within 90 days on "protecting IVF access and aggressively reducing out-of-pocket and health plan costs for IVF
kalshi_related	OK	1.0s	1	1 related markets / summaries. series KXFREEIVF: 0 markets (skipped 1 no-signal) \| keyword 'IVF': ok \| keyword 'fertility': no matches
polymarket_related	OK	1.0s	0	Scanned 100 active Polymarket markets, kept 0 matches. keyword 'IVF': 0 markets \| keyword 'fertility': 0 markets \| keyword 'Trump IVF': 0 markets
congress_bills	OK	4.6s	7	Found 7 bills matching 'in vitro fertilization coverage'.
gdelt_news	OK	218.9s	0	GDELT: 0 articles across 3 queries (lookback=180d). 'Trump IVF free': error GDELT rate-limited after retries (429) \| 'IVF executive order': error GDELT rate-limited after retries (429) \| 'TrumpRx IVF': error GDELT rate-limited after retries (429)
wikipedia	OK	1.0s	2	Fetched 2 Wikipedia entries (1 missing pages).

3. Evidence Brief Sonnet 5 · 7502 chars

# Current state No federal action has yet made any IVF cycle fully free; the administration has produced only a study-mandate EO, a partial drug-discount deal (TrumpRx, ~70-84% off select fertility drugs only), and a proposed (not finalized) rule enabling standalone fertility insurance — none of which zeroes out total cycle cost ($15,000-$35,000). Kalshi prices the event at 13%. # Timeline of key events - 2025-02-18: Trump signs EO 14216 directing 90-day policy recommendations on reducing IVF costs; no concrete mandate. (confirmed, resolve.org) - 2025-05: 90-day deadline passes with no recommendations released publicly. (confirmed, nbcnews.com) - 2025-10-16: White House announces TrumpRx deal with EMD Serono for 70-84% discounts on three fertility drugs (drugs only, not procedure); encourages (does not mandate) employer IVF benefits. (confirmed, CNN/KFF) - 2026-02-05: TrumpRx.gov platform launches with discounted fertility drug pricing. (confirmed, preludefertility.com) - 2026-03-26: HOPE with Fertility Services Act (HR 8119) introduced in House. (confirmed, congress.gov) - 2026-05: DOL/HHS/Treasury propose rule allowing standalone fertility insurance plans for employers; explicitly falls short of mandate/subsidy; 60-day comment period post-publication. (confirmed, PBS) - 2026-05-21: CNN/KFF assessment: no policy to date amounts to full coverage or cost elimination; officials concede shortfall vs. campaign promise. (confirmed) - 2026-07-23: Right to IVF Act of 2026 (S 5108, Duckworth) referred to HELP Committee — no floor action noted. (confirmed, congress.gov) - TRICARE/military IVF coverage: mixed congressional action; Speaker Johnson stripped TRICARE fertility coverage from NDAA; Bipartisan IVF for Military Families Act still pending. (reported, ASRM) # Event Will a Trump administration action eliminate the out-of-pocket cost of at least one full IVF cycle before Jan 20, 2029? # Outcomes to forecast - Yes - No # Kalshi market anchor KXFREEIVF-29 current YES price: **13%**. Flat over 7 days (+0%), down 3pts over 30 days; range 9-39% over 277 days (implying early optimism has decayed). Thin market: ~120 contracts/day average volume (related-market feed shows only ~21/day recently, range 13-17%). No momentum toward Yes. # Sub-question answers 1. **Kalshi price/trend**: 13% now; peaked as high as 39% earlier (likely near Feb 2025 EO announcement hype) and declined to low-teens as concrete action underdelivered; largely flat since Oct 2025 TrumpRx announcement — market treated it as insufficient. (kalshi_direct) 2. **Concrete actions**: Feb 2025 EO (study only, no results delivered by May 2025 deadline); Oct 2025 TrumpRx drug discount deal (70-84% off select drugs only, not full cycle); May 2026 proposed (unfinalized) rule for standalone fertility insurance, explicitly not a mandate or subsidy. None eliminates full cycle cost — best estimate ~$2,200 drug savings vs. $15,000-$35,000 total cost. (claude_news/CNN/KFF/PBS) 3. **Pending legislation**: Right to IVF Act of 2026 (S.5108, Duckworth, Dem) and HOPE with Fertility Services Act (HR.8119, Nunn, R) both stuck in committee as of mid-2026; no floor votes reported; Republican Congress unlikely to pass a Democrat-led mandate bill, and GOP bill (HOPE Act) scope/cost-elimination unclear. TRICARE-specific fertility mandate was removed from NDAA by Speaker Johnson. (congress_bills, ASRM) 4. **Further rule/mandate signaled**: Only the proposed May 2026 DOL/HHS/Treasury rule (standalone insurance option), still in comment period as of research date; no direct-payment or full-mandate program with a timeline announced. (PBS) 5. **Kalshi resolution treatment of partial measures**: Rules require an action that "eliminates the cost of at least one IVF cycle" — drug discounts, insurance mandates with copays, or population-limited coverage (military/federal employees) would NOT qualify unless they zero out total out-of-pocket cost for at least one full cycle. Current measures are explicitly partial. (inferred from description; consistent with market price decline) 6. **Polymarket/other markets**: No matching Polymarket markets found (0 matches scanned). Kalshi-related search shows only this same ticker, confirming no cross-market disagreement data available. 7. **Base rate for healthcare cost-elimination promises**: Not directly quantified in research, but historical analogy (e.g., "$2,000 drug price caps," "lowest-ever premiums" promises) suggests full delivery on sweeping "free" healthcare pledges within one term is rare, especially without legislation; qualitative sourcing (KFF, CNN) frames the IVF pledge as similarly falling short. # Key facts (high-confidence, factual) 1. [Kalshi] Current YES price 13%, down from range highs of 39%. 2. [resolve.org/NBC] Feb 2025 EO produced no substantive policy by its own 90-day deadline. 3. [CNN/KFF] Oct 2025 TrumpRx deal only discounts three fertility drugs (70-84% off), not procedure costs. 4. [PBS] May 2026 proposed rule permits (does not mandate) standalone fertility insurance; unfinalized. 5. [CNN, May 2026] KFF's Usha Ranji: policies "do not amount to full coverage or full access." 6. [congress.gov] Right to IVF Act (S.5108) and HOPE Act (HR.8119) both pending in committee, no passage. 7. [ASRM] TRICARE fertility coverage stripped from NDAA by Speaker Johnson. # Cross-market signals - Kalshi related: only this same market found; no arbitrage signal. - Polymarket: no matching markets (0/100 scanned). - Sportsbook implied: not applicable. # Analyst opinions and speculation - KFF (Ranji): current measures fall well short of "free IVF" promise; no mandate exists. - ASRM: legislative path fragmented — bipartisan military-focused bills exist but face internal GOP resistance (NDAA removal). - Market pricing (13%, declining) implicitly reflects analyst consensus that full elimination is unlikely absent new legislation or an unanticipated executive mandate. # Directional lean per outcome - **Yes**: Requires either (a) a strengthened executive mandate forcing insurers/employers to cover full IVF cost, or (b) passage of federal legislation (Right to IVF Act or similar) before 2029 — both currently stalled; TrumpRx/rule proposals show administration prefers voluntary/discount approaches over mandates. - **No**: Two-plus years of administration action (EO, TrumpRx, proposed rule) have consistently avoided full-cost elimination and explicitly disclaimed mandates; Congress bills stalled in committee; market price trending down supports No as base case. # Gaps / unknowns - No visibility into whether the May 2026 proposed rule will be finalized, and if so, whether it could evolve into a de facto free-cycle mechanism (unlikely per current framing). - Unclear whether future TrumpRx drug expansions could eventually cover near-100% of a "minimal" cycle's drug costs (edge case for partial Yes interpretation) — not addressed by resolution language provided. - No independent Polymarket cross-check available. - 2027-2028 legislative session dynamics (post-2026 midterms) unknown — could shift Congressional control and bill prospects. # Calibration anchors - Kalshi current YES price: 13% (anchor), down from historical high of 39%, thin volume (~120/day). - Precedent: high-profile healthcare cost-elimination promises (e.g., drug price caps, "free" services) historically under-deliver within single terms absent legislation — consistent with declining market price and analyst consensus of shortfall.

4. Forecasters Fable 5.1 + GPT-5.6 Sol · in parallel

claude-fable-5-1

62% conf

Yes	11%
No	89%

Kalshi anchors YES at 13%, down from a 39% peak as concrete actions consistently underdelivered: the Feb 2025 EO produced nothing by its own deadline, TrumpRx only discounts three drugs (~$2,200 vs. $15,000-$35,000 cycle cost), and the May 2026 proposed rule explicitly disclaims any mandate or subsidy. Both federal IVF bills are stalled in committee and Speaker Johnson stripped even TRICARE fertility coverage from the NDAA, signaling GOP resistance to mandates. The administration's revealed preference for voluntary/discount mechanisms makes a full cost-elimination action unlikely absent a major shift, though ~2.5 years remain and resolution ambiguity around population-limited coverage (military/federal employees) or a post-midterm legislative surprise keeps a modest tail. I lean slightly below the market given the thin volume and the clear direction of evidence.

gpt-5.6-sol

72% conf

Yes	12%
No	88%

The 13% Kalshi YES price is the primary anchor, with its decline from 39% indicating that early optimism surrounding the 2025 executive order dissipated as concrete action underdelivered. The executive order missed its policy-recommendation deadline, TrumpRx covers only selected drugs, and the proposed insurance rule neither mandates coverage nor eliminates out-of-pocket costs. Legislative routes remain stalled in committee, while removal of TRICARE fertility coverage from the NDAA demonstrates material Republican resistance even to narrower coverage. With no competing cross-market signal and current policy consistently favoring voluntary discounts over full subsidies, I shade YES slightly below Kalshi to 12%.

5. Devil's Advocate Sonnet 5 · red-team critique

Both forecasts converge almost exactly on the Kalshi price (11-12% vs 13%) with minimal independent reasoning about why the true probability might diverge from the thin, low-volume market (~120 contracts/day, related feed only ~21/day) — neither addresses that thin markets can be stale/mispriced rather than efficient, so anchoring this tightly may understate uncertainty in either direction.

Neither forecaster meaningfully engages with the "Gaps/unknowns" section, particularly the 2027-2028 post-midterm legislative shift possibility — a Democratic House takeover could revive the Right to IVF Act or similar mandate legislation with ~2 years still remaining before the Jan 2029 close, which deserves more explicit weight than a vague "tail" mention.

Both treat "population-limited coverage" (military/federal employees, TRICARE) as likely non-qualifying, but neither explores the edge case where a narrow but complete zero-cost benefit for a specific population (e.g., federal employees via OPM rule, or a finalized TRICARE mandate reinstated post-NDAA fight) could satisfy "at least one full IVF cycle" resolution language — this ambiguity is flagged in the brief but underexplored as a path to Yes.

Neither forecast considers that Trump's personal political incentive (having explicitly promised "free IVF" as a campaign pledge) could motivate a late-term unilateral executive action or emergency mandate to claim a deliverable before 2028 elections/legacy considerations, independent of the currently stalled legislative and rulemaking tracks.

The reasoning in both rationales is highly redundant (nearly identical bullet points and evidence citations), suggesting anchoring/copying rather than independent verification — this reduces the diagnostic value of having two forecasts and masks whether either considered alternative scenarios (e.g., a broader TrumpRx drug-cost expansion someday covering ~100% of a "minimal" cycle's drug costs, explicitly flagged as an unresolved edge case in the brief).

Both forecasts assign confidence (0.62, 0.72) that seems arbitrary given how closely their point estimates track Kalshi — the stated confidence levels aren't clearly justified by any independent variance estimate, and neither explains why they differ from each other despite nearly identical rationales and probabilities.

6. Aggregator Fable 5.1 · final calibrated forecast

13% (67% confidence)

Yes: 13% No: 87%

Every concrete action to date (Feb 2025 EO, TrumpRx drug discounts, the proposed standalone-insurance rule) has stopped well short of eliminating a full IVF cycle's cost and the administration has explicitly disclaimed mandates or subsidies, while both federal bills are stalled and GOP leadership stripped even TRICARE fertility coverage from the NDAA. The critique correctly notes that the two forecasts simply echoed the market without weighing tail paths — a post-midterm legislative shift, a narrowly targeted but fully zero-cost benefit (e.g., federal employees or military) that might satisfy the 'at least one full cycle' language, or a late-term unilateral action motivated by the explicit campaign pledge with ~2.5 years remaining. Those tails justify not shading below the market despite the clear negative trend, but they are not strong enough to move above it given the thin, declining price and consistent revealed preference for voluntary/discount approaches. I hold at the Kalshi anchor of 13% Yes.

Pipeline Timing

Total pipeline time: 308.4s

Per-tool research timings shown in the Research section above.